Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The molecular pathology of ovarian serous borderline tumors.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2016

Malpica A, Wong K-K

Abstract excerpt

Molecular studies in ovarian serous borderline tumors (OSBTs) have been used to understand different aspects of this neoplasm. (i) Pathogenesis, Kras and Braf mutations represent very early events in the tumorigenesis of OSBT as both are detected in serous cystadenomas associated with OSBTs. In contrast, serous cystadenomas without OSBTs do not show Kras or Braf mutations. In OSBTs, Kras mutations range from 17%...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Transformation, Neoplastic
Share to Cystadenocarcinoma, Serous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Molecular Targeted Therapy

Share to Ovarian Neoplasms

Share to Pathology, Molecular

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 27141064
DOI: 10.1093/annonc/mdw089
PMCID: PMC4852276

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The molecular pathology of ovarian serous borderline tumors.PMID 27141064Read ↗

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.Semantic proximity Read ↗

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.Semantic proximity Read ↗

Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma.Semantic proximity Read ↗

Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.Semantic proximity Read ↗

Molecular Landscape of Borderline Ovarian Tumors: A Systematic ReviewSemantic proximity Read ↗

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.Semantic proximity Read ↗

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.Semantic proximity Read ↗

High-grade Anaplastic Transformation of Ovarian Serous Borderline Tumor: A Distinctive Morphology With Abundant Dense Eosinophilic Cytoplasm and Dismal Prognosis.Semantic proximity Read ↗

Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.Semantic proximity Read ↗

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers.Semantic proximity Read ↗

Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges.Semantic proximity Read ↗

KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.